/Revvity%20Inc_%20stock%20chart%20and%20logo-by%20T_Schneider%20via%20Shutterstock.jpg)
Waltham, Massachusetts-based Revvity, Inc. (RVTY) provides health sciences solutions, technologies, and services. Valued at $14.8 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. The leading research and diagnostic company is expected to announce its fiscal third-quarter earnings for 2024 before the market opens on Monday, November 4.
Ahead of the event, analysts expect RVTY to report a profit of $1.13 per share on a diluted basis, down 4.2% from $1.18 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing on another occasion. Revvity reported an EPS of $1.22 for the last quarter, exceeding the consensus estimate by 8%, thanks to stronger-than-expected demand for its diagnostic products.